The East Midlands Neuroendocrine Tumour (NET) service has received Centre of Excellence accreditation from the European Neuroendocrine Tumor Society (ENETS).
In a significant milestone for specialist cancer care in the region, the UHL-based service has become one of only a small number of accredited centres across the UK.
NETs are a diverse group of uncommon tumours that can develop in organs including the bowel, pancreas and lungs. Often described as “hidden cancer”, NET symptoms can be vague and easily mistaken for more common conditions – meaning that on average, patients can wait for five years or even longer for a diagnosis. Both the number of new diagnoses and the number of people living with neuroendocrine cancer are increasing, making access to specialist expertise and continuing support increasingly important.
Leicester’s multi-disciplinary service, which was established nine years ago, brings together professionals from different specialties to review cases and agree individualised treatment recommendations for patients across the region. This coordinated approach supports patients throughout their journey from diagnosis to treatment and longer-term, follow-up care.
ENETS Centre of Excellence accreditation follows a rigorous independent assessment against international standards. The process examines the organisation and quality of care, multidisciplinary collaboration, patient involvement, research, clinical governance and arrangements for ongoing monitoring and follow-up.
Mr Deep Malde, Consultant Hepatobiliary and Pancreatic Surgeon, and lead clinician for the East Midlands NET Service, said: “This is a proud moment for our entire team, and reflects nine years of dedication, perseverance and collaboration, alongside the commitment that our colleagues show to patients every day.
“The accreditation provides the team with the foundation for further improvements in patient care, education and research. Our focus remains on building on this achievement, strengthening patient support and continuing to develop a service that responds to the needs of people living with neuroendocrine tumours.
“Above all, this achievement belongs to the whole team, who are united by the aim of providing better care for patients with complex tumours and support for their loved ones. We are grateful to our clinical, nursing, diagnostic, administrative and support colleagues, and to our patients and partner services, who have helped us reach this milestone.”
Julie Diamond, patient ambassador for Neuroendocrine Cancer UK, visited the LRI on World Neuroendocrine Cancer Day (10 November) to help raise awareness of this group of rare cancers among the public and medical community – with a particular focus on highlighting the importance of supporting those affected, and of ensuring timely access to specialist care.
Julie, from Glenfield, was referred to the NET service in October 2025 by Consultant Endocrinologist, Professor Miles Levy. She received pancreatic radiofrequency ablation treatment before being referred for further oncology treatment at St Luke’s Hospital, Market Harborough.

Julie said: “My experience with the NET service has always been good, and it’s no surprise at all to me that they have received Centre of Excellence accreditation. I know that in order to get there, they have to operate to very high standards, and they have proved all the way through that they have all the attributes.
“I hope that this achievement opens up more avenues for patients like me in the future, through research into new treatments.”
Mr Deep Malde added: “By encouraging conversations, sharing information and listening to patients with persistent, unexplained symptoms, we can help improve recognition and support earlier diagnosis – avoiding delays to treatment, which can have a significant impact.”